Class Action Lawsuit Filed for ESSA Pharma Inc. Investors
Levi & Korsinsky, LLP has taken a significant step by notifying investors of ESSA Pharma Inc. (EPIX) regarding a class action securities lawsuit. This action aims to recover losses for investors adversely affected by alleged securities fraud. If you have invested in ESSA Pharma Inc., it's essential to understand the implications of this lawsuit and how it may affect you.
Understanding the Class Definition
The class action lawsuit targets shareholders of ESSA Pharma Inc. who purchased shares during a specific period. The allegations include false statements made by the company and a lack of disclosure regarding the efficacy of certain treatments. It's a crucial time for investors to evaluate their position and consider joining the class action.
Key Allegations in the Lawsuit
Investors need to be aware that the lawsuit highlights several concerning allegations against ESSA Pharma Inc. The complaints assert that the efficacy of masofaniten, particularly in combination with enzalutamide for treating prostate cancer, was overstated. These claims raise important questions about the company's communications and the validity of its treatment claims.
Requesting Lead Plaintiff Status
If you have suffered financial losses during the outlined timeframe, you have until March 25, 2025, to request the court appoint you as a lead plaintiff. Being a lead plaintiff could potentially enhance your standing within the class action, but it's not a prerequisite to share in any recovery the lawsuit might yield.
Zero Costs for Class Members
One of the most significant advantages for class members is the assurance that participation in the lawsuit won't incur any out-of-pocket costs or fees. This means that you can pursue potential compensation without financial risk, making it accessible for all affected investors.
Why Choose Levi & Korsinsky for Your Legal Representation?
Levi & Korsinsky boasts a two-decade track record of holding corporations accountable for their actions. With a dedicated team of over 70 employees, they specialize in complex securities litigation and have successfully secured substantial recoveries for aggrieved shareholders. The firm's reputation is bolstered by its consistent recognition as one of the top securities litigation firms across the United States.
Contact Information
For more information or to express your interest in joining the lawsuit, you can reach out to:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit focuses on alleged securities fraud affecting shareholders of ESSA Pharma Inc. during a defined period.
How can I participate in the lawsuit?
If you faced losses, you can request to be appointed as a lead plaintiff by a specific deadline without any cost involved.
What are the allegations in the lawsuit?
The lawsuit alleges that ESSA Pharma Inc. made false claims regarding the efficacy of masofaniten and misled investors about treatment outcomes.
Who can be considered a class member?
Individuals who purchased ESSA Pharma Inc. shares during the relevant time frame may qualify as class members.
What experience does Levi & Korsinsky have?
Levi & Korsinsky has a broad experience in securities litigation, boasting a solid track record of successful legal actions on behalf of investors.
